Hoth Therapeutics
OverviewSuggest Edit
Hoth Therapeutics is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Company also develops the BioLexa Platform, a product candidate intended to prevent the symptom-triggering flare-ups before they occur.
| Type | Public | |
| HQ | New York, NY, US | Map |
| Website | hoththerapeutics.com |
Recent NewsAll News
- Thinking about buying stock in Hoth Therapeutics, Castor Maritime, Clover Health Investments, Naked Brand, or Virgin Galactic?
- Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm
- Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
- Hoth Therapeutics Retains RedChip to Increase Investor Awareness
Hoth Therapeutics Office Locations
Hoth Therapeutics has an office in New York
New York, NY, US (HQ)
1 Rockefeller Plaza, 10th Floor
Hoth Therapeutics Financials and Metrics
Hoth Therapeutics Revenue
| USD | |
|---|---|
Net income (Q1, 2021) | (4.3m) |
EBIT (Q1, 2021) | (4.3m) |
Market capitalization (14-May-2021) | 31.0m |
Closing stock price (14-May-2021) | 1.4 |
Cash (31-Mar-2021) | 19.3m |
Hoth Therapeutics's current market capitalization is $31 m.
Annual
Annual
Annual
Quarterly
| USD | Q3, 2017 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|
Net Income | (1.7m) | (1.9m) | (829.4k) | (2.1m) | (3.8m) | (1.8m) | (4.3m) | (4.3m) |
Depreciation and Amortization | 916.0 | 302.0 | 608.0 | 916.0 | 305.0 | 610.0 | ||
Accounts Payable | 1.5k | (22.2k) | (71.7k) | 65.0k | (117.0k) | 113.7k | (104.5k) | 453.9k |
Cash From Operating Activities | (240.3k) | (1.6m) | (764.0k) | (1.8m) | (3.4m) | (1.6m) | (4.0m) | (2.7m) |
Hoth Therapeutics Cybersecurity Score
Hoth Therapeutics Online and Social Media Presence
Hoth Therapeutics's Trends
Hoth Therapeutics News and Updates
April 20, 2021
Thinking about buying stock in Hoth Therapeutics, Castor Maritime, Clover Health Investments, Naked Brand, or Virgin Galactic?
NEW YORK, April 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOTH, CTRM, CLOV, NAKD, and SPCE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...
April 05, 2021
Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm
NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for...
March 01, 2021
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also...
February 25, 2021
Hoth Therapeutics Retains RedChip to Increase Investor Awareness
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts. RedChip is the leader in investor relations, financial media, and research...
February 02, 2021
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications. Drug Pipeline Highlights:...
January 20, 2021
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the...
Hoth Therapeutics Blogs
April 30, 2019
HOTH THERAPEUTICS, INC. TO PRESENT AT THE THINKEQUITY CONFERENCE
NEW YORK, April 30, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today annou…
Hoth Therapeutics Frequently Asked Questions
How many employees does Hoth Therapeutics have?
Hoth Therapeutics has 2 employees.
Who are Hoth Therapeutics competitors?
Competitors of Hoth Therapeutics include Alexion Pharmaceuticals, KiOmed Pharma and Veloxis Pharmaceuticals.
Where is Hoth Therapeutics headquarters?
Hoth Therapeutics headquarters is located at 1 Rockefeller Plaza, 10th Floor, New York.
Where are Hoth Therapeutics offices?
Hoth Therapeutics has an office in New York.
How many offices does Hoth Therapeutics have?
Hoth Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies